AZN - AstraZeneca PLC

NYSE - NYSE Delayed price. Currency in USD
34.65
-0.13 (-0.37%)
At close: 4:02PM EDT

34.70 +0.05 (0.15%)
After hours: 4:11PM EDT

Stock chart is not supported by your current browser
Previous close34.78
Open34.66
Bid0.00 x 0
Ask0.00 x 0
Day's range34.60 - 34.81
52-week range25.55 - 35.60
Volume3,782,718
Avg. volume5,013,927
Market cap83.54B
Beta0.65
PE ratio (TTM)22.73
EPS (TTM)N/A
Earnings dateN/A
Forward Dividend & Yield0.90 (2.63%)
Ex-dividend date2017-08-09
1y target estN/A
Trade prices are not sourced from all markets
  • Market Realist13 hours ago

    What AstraZeneca’s 3Q17 Performance Tells Us

    AZN stock rose ~0.9% in 3Q17 and has risen ~26.9% YTD (year-to-date) as of October 16.

  • Reuters - UK Focus19 hours ago

    Astra and Merck win speedy review for Lynparza in breast cancer

    U.S. regulators have granted a priority review to AstraZeneca's ovarian cancer drug Lynparza as a treatment for breast cancer, putting it on track for potential approval in the new disease area during ...

  • Reuters - UK Focus2 days ago

    Chi-Med, AstraZeneca lung cancer drug shrinks resistant tumours

    LONDON, Oct (Shenzhen: 000069.SZ - news) 17 (Reuters) - An experimental cancer drug discovered by Hutchison China MediTech has demonstrated promising activity in shrinking tumours in lung cancer patients whose disease had worsened following treatment with approved medicines. The treatment, which Hutchison China MediTech or "Chi-Med" is developing with AstraZeneca (NYSE: AZN - news) , is one of a new wave of innovative medicines coming out of Chinese research labs as the country flexes its muscles in drug discovery. Results from small-scale studies presented on Tuesday at a medical meeting in Japan showed that adding savolitinib to either AstraZeneca's Tagrisso or Iressa improved responses.

  • Foreign Stock Roundup: Roche Gets FDA Nod for Zika Test, Shell to Buy NewMotion
    Zacks2 days ago

    Foreign Stock Roundup: Roche Gets FDA Nod for Zika Test, Shell to Buy NewMotion

    Foreign markets remain undeterred by discouraging events, notching up weekly gains.

  • Bloomberg3 days ago

    Drug Companies Fear Brexit Will Hit Medicine Trade

    Time is running short for a Brexit agreement that will allow the free movement of medicines through the U.K. and the rest of the European Union.

  • 5 Large-Cap Drug Stocks Well Poised to Beat on Q3 Earnings
    Zacks5 days ago

    5 Large-Cap Drug Stocks Well Poised to Beat on Q3 Earnings

    The pharma/biotech sector has a number of things going in its favor.

  • Cancer Space Update: Lung & Breast Cancer Studies in Focus
    Zacks5 days ago

    Cancer Space Update: Lung & Breast Cancer Studies in Focus

    While Lilly announced failure of a lung cancer study, AstraZeneca's Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication.

  • Lilly's Verzenio Gets Priority Review in First-Line Setting
    Zacks6 days ago

    Lilly's Verzenio Gets Priority Review in First-Line Setting

    Eli Lilly and Company (LLY) announced that the FDA has granted priority review to its new drug application for Verzenio (abemaciclib) for the first-line treatment of advanced breast cancer.

  • AstraZeneca's Tagrisso Gets Breakthrough Therapy Designation
    Zacks9 days ago

    AstraZeneca's Tagrisso Gets Breakthrough Therapy Designation

    AstraZeneca (AZN) obtained Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer.

  • Reuters - UK Focus13 days ago

    Drug industry gives up legal battle over new UK cost curbs

    LONDON, Oct (Shenzhen: 000069.SZ - news) 5 (Reuters) - Britain's pharmaceuticals industry has thrown in the towel in a legal battle over new cost curbs imposed by the state-run health service, after failing to secure a judicial review. Drugmakers argue the curbs, imposed earlier this year, have the potential to cause significant delays for patients waiting for treatment for a range of conditions, including for cancer, heart disease and diabetes. The Association of the British Pharmaceutical Industry (ABPI) said on Thursday, however, that its board had agreed unanimously not to appeal after a High Court judge turned down its review application on Wednesday.

  • Reuters - UK Focus14 days ago

    Drug industry fails to win judicial review of new UK cost curbs

    LONDON, Oct (Shenzhen: 000069.SZ - news) 4 (Reuters) - Britain's pharmaceuticals industry failed to secure a judicial review of new cost curbs, which mean drugs costing NHS England more than 20 million pounds ($26 mln) annually no longer get automatic funding. The Association of the British Pharmaceutical Industry (ABPI) had sought to challenge the additional hurdle to drug uptake that was implemented by the National Institute for Health and Care Excellence (NICE (Other OTC: NCSYF - news) ) earlier this year. On Wednesday it said it was disappointed the judicial review application had been turned down.

  • These Biotechs Slump As Report Suggests Discounting Their Drugs
    Investor's Business Daily15 days ago

    These Biotechs Slump As Report Suggests Discounting Their Drugs

    AstraZeneca and Tesaro stocks were in a slump Tuesday, a day after an institute doubted the cost-effectiveness of their cancer drugs.

  • Tell us how Brexit will work, British companies demand
    Reuters17 days ago

    Tell us how Brexit will work, British companies demand

    British companies including pharmaceuticals giant AstraZeneca urged the government on Monday to agree a three-year Brexit transitional deal to ease the uncertainty hampering investment decisions and the economy. Britain's biggest companies have become increasingly alarmed by the slow progress of Brexit negotiations and the prospect the country could crash out of the world's biggest trading bloc without a deal in 2019. Prime Minister Theresa May vowed in a speech last month to seek a two-year transition deal to help reduce the disruption, but her efforts were overshadowed by a challenge from Foreign Secretary Boris Johnson who has set out his own terms for Britain leaving the European Union.

  • Reuters - UK Focus17 days ago

    Tell us how Brexit will work, British companies demand

    MANCHESTER, England, Oct (Shenzhen: 000069.SZ - news) 2 (Reuters) - British companies including pharmaceuticals giant AstraZeneca (NYSE: AZN - news) urged the government on Monday to agree a three-year Brexit transitional deal to ease the uncertainty hampering investment decisions and the economy. Britain's biggest companies have become increasingly alarmed by the slow progress of Brexit negotiations and the prospect the country could crash out of the world's biggest trading bloc without a deal in 2019. Prime Minister Theresa May vowed in a speech last month to seek a two-year transition deal to help reduce the disruption, but her efforts were overshadowed by a challenge from Foreign Secretary Boris Johnson who has set out his own terms for Britain leaving the European Union.

  • Reuters17 days ago

    Drugs firm AstraZeneca wants three-year Brexit transition

    British pharmaceuticals giant AstraZeneca (AZN.L) wants a transition period of at least three years when Britain leaves the European Union in 2019 and more clarity on what will happen in the longer term, its chairman said on Monday. Uncertainty about what Britain's relations with the EU will look like after March 2019 are hurting investment in the world's fifth largest economy. AstraZeneca Chairman Leif Johansson said the firm wanted "at least three years" as a transition period, "and very early in that period, we need to know what to expect in years four, five and six," he said told the Swedish daily Dagens Nyheter.

  • Drugs firm AstraZeneca wants three-year Brexit transition
    Reuters17 days ago

    Drugs firm AstraZeneca wants three-year Brexit transition

    British pharmaceuticals giant AstraZeneca (AZN.L) wants a transition period of at least three years when Britain leaves the European Union in 2019 and more clarity on what will happen in the longer term, its chairman said on Monday. Uncertainty about what Britain's relations with the EU will look like after March 2019 are hurting investment in the world's fifth largest economy. AstraZeneca Chairman Leif Johansson said the firm wanted "at least three years" as a transition period, "and very early in that period, we need to know what to expect in years four, five and six," he said told the Swedish daily Dagens Nyheter.

  • Reuters - UK Focus17 days ago

    Drugs firm AstraZeneca wants three-year Brexit transition

    STOCKHOLM, Oct (Shenzhen: 000069.SZ - news) 2 (Reuters) - British pharmaceuticals giant AstraZeneca (NYSE: AZN - news) wants a transition period of at least three years when Britain leaves the European Union in 2019 and more clarity on what will happen in the longer term, its chairman said on Monday. Uncertainty about what Britain's relations with the EU will look like after March 2019 are hurting investment in the world's fifth largest economy. AstraZeneca Chairman Leif Johansson said the firm wanted "at least three years" as a transition period, "and very early in that period, we need to know what to expect in years four, five and six," he said told the Swedish daily Dagens Nyheter.

  • Fool.co.uk20 days ago

    One growth stock I’d buy ahead of Astrazeneca plc

    If dividends aren't a priority, Paul Summers think this top growth stock might be a better bet than Astrazeneca plc (LON:AZN).

  • Fool.co.uk21 days ago

    2 turnaround stocks that could make you rich

    Bilaal Mohamed picks out two battered pharmaceutical stocks that could turn out to be excellent recovery plays.

  • Fool.co.uk21 days ago

    AstraZeneca plc isn’t the only pharma star that could make you rich

    AstraZeneca plc (LON: AZN) isn't the only pharma giant that could make you rich. Here Royston Wild looks at another drugs star with brilliant earnings potential.

  • Reuters - UK Focus23 days ago

    BUZZ-Top of the Street: Akzo Nobel, AstraZeneca, Statoil, Evonik

    A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** Societe Generale downgrades Akzo Nobel to "hold", as it remains unconvinced by the 2020 targets used ...

  • Reuters - UK Focus24 days ago

    AstraZeneca reports positive results for COPD drug

    AstraZeneca said it had attained positive top-line results in a trial for bronchodilator inhalation aerosol medicine for treatment of patients with moderate to very severe chronic obstructive pulmonary ...

  • Reuters - UK Focus27 days ago

    BUZZ-AstraZeneca: return-to-growth story - Bernstein

    ** Bernstein ups AstraZeneca to "outperform", citing big pipeline and potential take-out ** Broker sees co's LT EPS growth among the very best of the 9 major EI/US pharma cos it covers ** Bernstein ...

  • Reuters - UK Focus29 days ago

    GSK's new triple lung drug beats other modern inhalers in study

    GlaxoSmithKline produced clinical data on Wednesday showing its newly approved three-in-one inhaler reduced life-threatening attacks in chronic obstructive pulmonary disease patients more than other modern ...

  • Fool.co.uklast month

    Why I’d ditch this defensive dividend stock to buy AstraZeneca plc

    G A Chester argues AstraZeneca plc (LON:AZN) is the pick of two defensive dividend stocks.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes